Badanie Seltorexant w porównaniu z kwetiapiną XR jako terapią wspomagającą leki przeciwdepresyjne u dorosłych i osób w podeszłym wieku z dużymi zaburzeniami depresyjnymi z objawami bezsenności, którzy zareagowali niewystarczająco na leczenie przeciwdepresyjne
Podwójnie ślepe, randomizowane badanie w grupach równoległych z zastosowaniem kwetiapiny o przedłużonym uwalnianiu jako porównania w celu oceny skuteczności i bezpieczeństwa stosowania Seltorexant 20 mg jako terapii wspomagającej leki przeciwdepresyjne u dorosłych i pacjentów w podeszłym wieku z dużym zaburzeniem depresyjnym z objawami bezsenności, u których odpowiedź na leczenie przeciwdepresyjne była niewystarczająca
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Buenos Aires, Argentyna, 1058AAJ
- CENydET - Centro Neurobiologico y de Stress Traumatico
-
Buenos Aires, Argentyna, C1405BOA
- FunDaMos
-
Buenos Aires, Argentyna, 1199
- Hospital Italiano
-
Ciudad Autonoma Buenos Aires, Argentyna, C1428AQK
- Hospital Fleni
-
Córdoba, Argentyna, X5004AOA
- Instituto Privado Kremer
-
Córdoba, Argentyna, 5000
- Fundacion Lennox
-
Córdoba, Argentyna, X5006IKK
- Centro Medico Luquez
-
La Plata, Argentyna, Thanks
- Clinica Privada de Salud Mental Santa Teresa de Ávila
-
La Plata, Argentyna, 1902
- CENPIA
-
Mendoza, Argentyna, M5502AWY
- CENAIN
-
San Miguel de Tucumán, Argentyna, 4000
- Clinica Mayo de UMCB
-
-
-
-
-
Bruges, Belgia, 8310
- AZ Sint-Lucas
-
Sint-Niklaas, Belgia, 9100
- AZ Nikolaas
-
-
-
-
-
Pleven, Bułgaria, 5800
- Medical Center Medconsult-Pleven
-
Plovdiv, Bułgaria, 4028
- MC 'Hipokrat - N', EOOD
-
Rousse, Bułgaria, 7003
- Mental Health Center - Rousse
-
Sofia, Bułgaria, 1680
- Medical Center Intermedica, OOD
-
Sofia, Bułgaria, 1113
- Medical Center St. Naum
-
Sofia, Bułgaria, 1784
- MC 'Synexus Sofia' EOOD
-
Stara Zagora, Bułgaria, 6003
- UMHAT Prof. Dr. St. Kirkovich AD
-
Stara Zagora, Bułgaria, 6000
- MC 'Synexus Sofia' EOOD
-
Tzarev Brod, Bułgaria, 9747
- State Psychiatric Hospital - Tzarev Brod
-
Varna, Bułgaria, 9020
- Diagnostic Consulting Center Mladost - M Varna
-
Veliko Tarnovo, Bułgaria, 5000
- Mental Health Center - Veliko Tarnovo EOOD
-
-
-
-
-
Brno, Czechy, 60200
- Psychiatricka ambulance Saint Anne s.r.o.
-
Hradec Králové, Czechy, 500 09
- NeuropsychiatrieHK, s.r.o.
-
Pilsen, Czechy, 301 00
- A Shine S R O
-
Prague, Czechy, 100 00
- Clintrial s r o
-
Prague, Czechy, 160 00
- NeuropsychiatrieHK, s.r.o.
-
Prague, Czechy, 10000
- AD71 s.r.o.
-
Prague, Czechy, 186 00
- Institut Neuropsychiatricke pece
-
-
-
-
Nova Scotia
-
Sydney, Nova Scotia, Kanada, B1P 1E1
- A.K. Munshi Medical Inc.
-
-
Ontario
-
Toronto, Ontario, Kanada, M3J 2C5
- Canadian Phase Onward
-
-
Quebec
-
Montreal, Quebec, Kanada, H1M 1B1
- Clinique Force Medic (GCP Trials)
-
-
-
-
-
Kaunas, Litwa, 48259
- Kaunas Silainiu Outpatient Clinic, Public Institution
-
Kaunas, Litwa, 53136
- Republic Kaunas Hospital
-
Kaunas, Litwa, LT-44279
- Romuvos Klinika, JSC
-
Kaunas, Litwa, LT-50009
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics
-
Vilnius, Litwa, 09112
- Zirmunai Mental Health Center, Public Institution
-
Vilnius, Litwa, 10309
- Vilnius Mental Health Center
-
Vilnius, Litwa, 10204
- Antakalnis Psychiatric Consultation Centre, Public Institution
-
Šilutė, Litwa, 99176
- Medical Center Puriena JSC
-
-
-
-
-
Ipoh, Malezja, 30990
- Hospital Raja Permaisuri Bainun
-
Johor Bahru, Malezja, 81200
- Hospital Permai
-
Pulau Pinang, Malezja, 10990
- Hospital Pulau Pinang
-
Seremban, Malezja, 70300
- Hospital Tuanku Jaafar
-
-
-
-
-
Bełchatów, Polska, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bialystok, Polska, 15-464
- Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
-
Bydgoszcz, Polska, 85-080
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, Polska, 80 546
- Centrum Badan Klinicznych PI House sp z o o
-
Lodz, Polska, 90-009
- Specjalistyczna Indywidualna Praktyka Lekarska
-
Lodz, Polska, 90-368
- CCBR - Lodz - PL
-
Lublin, Polska, 20-582
- Specjalistyczna Praktyka Lekarska Marek Domanski
-
Poznan, Polska, 60-702
- Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
-
Warsaw, Polska, 01 737
- Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
-
Warsaw, Polska, 02 957
- Instytut Psychiatrii I Neurologii
-
-
-
-
-
Engel's, Rosja, 413124
- Engels psychiatric hospital
-
Kemerovo, Rosja, 650036
- Kemerovo Regional Clinical Psychiatric Hospital
-
Lipetsk Region, Rosja, 399313
- GUZ Lipetsk Regional psychoneurological Hospital #1
-
Moscow, Rosja, 105082
- JSC Scientific Centre of Personalized Medicine
-
Moscow, Rosja, 107076
- FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
-
Moscow, Rosja, 107076
- Moscow Scientific Research Institute of Psychiatry
-
Omsk, Rosja, 644070
- Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
-
Saint Petersburg, Rosja, 192019
- St-Petersburg Bekhterev Psychoneurological Research Institute
-
Tomsk, Rosja, 634009
- Klinika StoLet Ltd
-
Yekaterinburg, Rosja, 620030
- Sverdlov Regional Psychiatric Clinical Hospital
-
-
-
-
-
Belgrade, Serbia, 11000
- University Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- General Hospital Euromedik
-
Belgrade, Serbia, 11000
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Belgrade, Serbia, 11000
- General Hospital Acibadem Bel Medic
-
Belgrade, Serbia, 11000
- Institute of Mental Health Serbia
-
Kovin, Serbia, 26220
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, Serbia, 34000
- University Clinical Center Kragujevac
-
Niš, Serbia, 18000
- Clinical Center Nis
-
Novi Kneževac, Serbia, 23330
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, Stany Zjednoczone, 85712
- SW Biomedical Research LLC
-
-
California
-
Culver City, California, Stany Zjednoczone, 90230
- Proscience Research Group
-
Encino, California, Stany Zjednoczone, 91316
- Pharmacology Research Institute
-
Garden Grove, California, Stany Zjednoczone, 92845
- Collaborative NeuroScience Network
-
Long Beach, California, Stany Zjednoczone, 90806
- Collaborative NeuroScience Network
-
Los Alamitos, California, Stany Zjednoczone, 90720
- Pharmacology Research Institute
-
Los Angeles, California, Stany Zjednoczone, 90025
- CalNeuro Research
-
Newport Beach, California, Stany Zjednoczone, 92660
- Pharmacology Research Institute
-
Orange, California, Stany Zjednoczone, 92868
- NRC Research Institute
-
Orange, California, Stany Zjednoczone, 92868
- Pacific Neuropsychiatric Specialists
-
Pico Rivera, California, Stany Zjednoczone, 90660
- CNRI-Los Angeles, LLC
-
Rancho Cucamonga, California, Stany Zjednoczone, 91730
- Prospective Research Innovations Inc
-
Redlands, California, Stany Zjednoczone, 92374
- Anderson Clinical Research
-
San Diego, California, Stany Zjednoczone, 92103
- University of California at San Diego
-
Santa Ana, California, Stany Zjednoczone, 92705
- CI Trials
-
Santa Ana, California, Stany Zjednoczone, 91704
- National Research Institute
-
Santee, California, Stany Zjednoczone, 92071
- CMB Clinical Trials
-
Sherman Oaks, California, Stany Zjednoczone, 91403
- Schuster Medical Research Institute
-
Upland, California, Stany Zjednoczone, 91786
- Pacific Clinical Research Medical Group
-
-
Connecticut
-
Hartford, Connecticut, Stany Zjednoczone, 06102
- Hartford Hospital
-
-
Florida
-
Doral, Florida, Stany Zjednoczone, 33166
- Moonshine Research Center, Inc
-
Hallandale, Florida, Stany Zjednoczone, 33009
- Velocity Clinical Research, Hallandale Beach
-
Hialeah, Florida, Stany Zjednoczone, 33012
- Indago Research & Health Center Inc
-
Hialeah, Florida, Stany Zjednoczone, 33012
- New Life Medical Research Center, Inc.
-
Hialeah, Florida, Stany Zjednoczone, 33013
- Amedica Research Institute Inc
-
Lakeland, Florida, Stany Zjednoczone, 33803
- Meridien Research
-
Miami, Florida, Stany Zjednoczone, 33122
- Premier Clinical Research
-
Miami, Florida, Stany Zjednoczone, 33125
- Global Medical Institutes
-
Miami, Florida, Stany Zjednoczone, 33137
- Miami Jewish Health System
-
Orlando, Florida, Stany Zjednoczone, 32806
- Synexus Research Orlando
-
Orlando, Florida, Stany Zjednoczone, 23801
- Clinical Neuroscience Solutions
-
Tampa, Florida, Stany Zjednoczone, 33612
- University of South Florida
-
The Villages, Florida, Stany Zjednoczone, 32162
- Compass Research LLC-Bioclinica Research
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30331
- Atlanta Center for Medical Research
-
Atlanta, Georgia, Stany Zjednoczone, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Stany Zjednoczone, 30030
- iResearch Atlanta LLC
-
Marietta, Georgia, Stany Zjednoczone, 30060
- Psych Atlanta, P.C.
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60634
- Chicago Research Center
-
Libertyville, Illinois, Stany Zjednoczone, 60048
- Capstone Clinical Research
-
Lisle, Illinois, Stany Zjednoczone, 60532
- Alexian Brothers Health System
-
Naperville, Illinois, Stany Zjednoczone, 60563
- Baber Research Group
-
Oakbrook Terrace, Illinois, Stany Zjednoczone, 60618
- Lemah Creek Clinical Research
-
-
Kansas
-
Wichita, Kansas, Stany Zjednoczone, 67214
- Ascension via Christi Research
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70115
- Riverstar Research
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21208
- Pharmasite Research, Inc.
-
-
Massachusetts
-
New Bedford, Massachusetts, Stany Zjednoczone, 02740
- BTC of New Bedford
-
Roslindale, Massachusetts, Stany Zjednoczone, 02135
- Boston Clinical Trials & Medical Research
-
-
Missouri
-
O'Fallon, Missouri, Stany Zjednoczone, 63368
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Stany Zjednoczone, 08755
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Stany Zjednoczone, 11235
- SPRI Clinical Trials, LLC
-
New York, New York, Stany Zjednoczone, 10128
- The Medical Research Network, LLC
-
New York, New York, Stany Zjednoczone, 10017
- Fieve Clinical Research Inc
-
Rochester, New York, Stany Zjednoczone, 14618 1609
- Finger Lakes Clinical Research
-
Staten Island, New York, Stany Zjednoczone, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27701
- Velocity Clinical Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
-
Dayton, Ohio, Stany Zjednoczone, 45417
- Midwest Clinical Research Center
-
North Canton, Ohio, Stany Zjednoczone, 44720
- Neuro Behavioral Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73112
- Sooner Clinical Research
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73118
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Pine Hill, Pennsylvania, Stany Zjednoczone, 08021
- Suburban Research Associates
-
Scranton, Pennsylvania, Stany Zjednoczone, 18503
- Global Medical Institutes
-
-
South Carolina
-
Mt. Pleasant, South Carolina, Stany Zjednoczone, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Bellaire, Texas, Stany Zjednoczone, 77401
- West Houston Clinical Research Service
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- North Texas Clinical Trials
-
Mansfield, Texas, Stany Zjednoczone, 76054
- Hawkins Psychiatry, PC
-
The Woodlands, Texas, Stany Zjednoczone, 77381
- Family Psychiatry of The Woodlands
-
Wichita Falls, Texas, Stany Zjednoczone, 76309
- Grayline Research Center
-
-
Utah
-
Clinton, Utah, Stany Zjednoczone, 84015
- Alpine Research Organization
-
Draper, Utah, Stany Zjednoczone, 84020
- Cedar Clinical Research
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22903
- University of Virginia
-
-
Washington
-
Bellevue, Washington, Stany Zjednoczone, 98007
- Northwest Clinical Research Center
-
Everett, Washington, Stany Zjednoczone, 98201
- Core Clinical Research
-
-
Wisconsin
-
Waukesha, Wisconsin, Stany Zjednoczone, 53188
- Cary J. Kohlenberg, MD, SC, dba, IPC Research.
-
-
-
-
-
Banská Bystrica, Słowacja, 97401
- Psychomed-Svatosavsky, s.r.o.
-
Bojnice, Słowacja, 97201
- Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
-
Košice, Słowacja, 040 11
- Epamed sro
-
Liptovský Mikuláš, Słowacja, 03123
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, Słowacja, 97901
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Trenčín, Słowacja, 91101
- FN Trencin
-
Trenčín, Słowacja, 91108
- Pro mente sana s.r.o.
-
Žilina, Słowacja, 1207
- Fakultna nemocnica s poliklinikou v Ziline
-
-
-
-
-
Hlevakha, Ukraina, 8631
- MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
-
Kharkiv, Ukraina, 61068
- Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
-
Kyiv, Ukraina, 04080
- Kyiv Territorial Medical Incorporation 'Psychiatry'
-
Kyiv, Ukraina, 1030
- Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
-
Kyiv, Ukraina, 1034
- Medical Center Health and Happy
-
Nove, Ukraina, 25491
- Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
-
Ternopil, Ukraina, 46020
- Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
-
Zaporizhzhya, Ukraina, 69600
- Zaporizhzhia Regional Clinical Hospital
-
-
-
-
-
Derby, Zjednoczone Królestwo, DE22 3LZ
- Kingsway Hospital
-
Greater Manchester, Zjednoczone Królestwo, M15 6SX
- Synexus
-
Harrogate, Zjednoczone Królestwo, HG1 2PW
- Garden Valleys Resource Centre
-
London, Zjednoczone Królestwo, SE5 8EF
- Kings College Hospital NHS Trust
-
Redruth, Zjednoczone Królestwo, TR15 2SP
- Cornwall Partnership Foundation Trust
-
-
-
-
-
Jelgava, Łotwa, LV-3008
- The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
-
Liepāja, Łotwa, LV-3401
- L. Keruze Practice in Psychiatry
-
Outpatient Centre of Psychiatry, Łotwa, LV-4601
- Hospital of Rezekne
-
Riga, Łotwa, LV-1002
- Riga Centre of Psychiatry and Narcology
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
- Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
- Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
- Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
- Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
- Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
- Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Seltorexant
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182. |
Participants will receive seltorexant over-encapsulated tablet orally. Participants will receive placebo over-encapsulated tablet matching to seltorexant orally. |
|
Aktywny komparator: Quetiapine Extended-Release (XR)
Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability. |
Participants will receive quetiapine XR capsule orally. Participants will receive placebo capsule matching to quetiapine XR orally. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Ramy czasowe: Week 26
|
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline to Week 26 in Weight
Ramy czasowe: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in weight was reported. |
Baseline (Day 1) and Week 26
|
|
Time to Potentially Treatment Related Discontinuation of Study Drug
Ramy czasowe: From first dose of study drug (Day 1) up to Week 30
|
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used. |
From first dose of study drug (Day 1) up to Week 30
|
|
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Ramy czasowe: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in MADRS-6 Total Score
Ramy czasowe: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Ramy czasowe: Baseline (Day 1) and Week 26
|
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Ramy czasowe: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Ramy czasowe: Week 26
|
Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Ramy czasowe: Week 26
|
Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Ramy czasowe: Week 26
|
Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported. |
Week 26
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- CR108810
- 42847922MDD3005 (Inny identyfikator: Janssen Research & Development, LLC)
- 2020-000341-14 (Numer EudraCT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .